# A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

> **NCT04615468** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** TQ-B3525

## Key facts

- **NCT ID:** NCT04615468
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2020-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615468, "A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04615468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*